J. Zalevsky

发表

Enhanced antibody half-life improves in vivo activity

G. A. Lazar, J. Desjarlais, G. Lazar, 2010, Nature Biotechnology.

Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic stage IV melanoma

J. Larkin, M. Hurwitz, M. Sznol, 2019 .

Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.

M. Hurwitz, M. Sznol, A. Balar, 2019, Journal of Clinical Oncology.

Soluble TNF Mediates the Transition from Pulmonary Inflammation to Fibrosis

G. Kollias, V. Aidinis, A. Kotanidou, 2006, PloS one.

primates Fc{gamma} receptor affinity enhances B-cell clearing in nonhuman The impact of Fc engineering on an anti-CD19 antibody: increased

E. Zhukovsky, J. Zalevsky, S. Karki, 2009 .

A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys

J. Zalevsky, C. Xia, G. Smithson, 2019, The Journal of Pharmacology and Experimental Therapeutics.

420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study

M. Hurwitz, M. Sznol, I. Puzanov, 2020 .

Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist

B. Comin-Anduix, A. Ribas, R. Tavaré, 2020, Nature Communications.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection

B. Ryffel, D. Szymkowski, S. Ezhevsky, 2007, The Journal of Immunology.

Suppressing Innate Immunity to Infection Attenuate Experimental Arthritis without Dominant-Negative Inhibitors of Soluble TNF

B. Ryffel, S. Ezhevsky, J. Zalevsky, 2007 .

Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).

V. Feher, J. Yano, J. Zalevsky, 2016, Bioorganic & medicinal chemistry letters.

Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus

C. Fanton, J. Zalevsky, R. Furie, 2022, Journal of translational autoimmunity.

Immunotherapy Bridge 2020 and Melanoma Bridge 2020: meeting abstracts

Brendan, J. McQuade, M. Hurwitz, 2021, Journal of Translational Medicine.

JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes*

B. Dahiyat, J. Olefsky, T. Imamura, 2005, Journal of Biological Chemistry.

Antibody-Dependent Cell-Mediated Cytotoxicity Overcomes NK Cell Resistance in MLL-Rearranged Leukemia Expressing Inhibitory KIR Ligands but Not Activating Ligands

Y. Li, J. Zalevsky, W. Leung, 2012, Clinical Cancer Research.

Suppresses Humoral Immunity in Systemic RIIb and B Cell Receptor Complex g Antibody-Mediated Coengagement of Fc

J. Desjarlais, D. Szymkowski, J. Zalevsky, 2011 .

NKTR-255, a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells.

J. Zalevsky, L. Madakamutil, K. Schluns, 2021, The Journal of clinical investigation.

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

M. Hurwitz, M. Sznol, I. Puzanov, 2021, Journal of Clinical Oncology.

Cancer Therapy : Preclinical Antibody-Dependent Cell-Mediated Cytotoxicity Overcomes NKCellResistance in MLL-RearrangedLeukemiaExpressing Inhibitory KIR Ligands but not Activating Ligands

J. Zalevsky, W. Leung, W. Chan, 2012 .

NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy

W. Rubas, J. Zalevsky, Yinyan Tang, 2021, Journal for ImmunoTherapy of Cancer.

Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.

M. Hurwitz, M. Sznol, A. Balar, 2022, European urology.

Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in Rodents

E. Navratilova, J. Zalevsky, F. Porreca, 2020, Cellular and Molecular Neurobiology.

Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy.

D. Ramies, A. Younes, K. Blum, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2

R. Mullins, J. Zalevsky, N. Bunnett, 2000, The Journal of cell biology.

Antibody-Mediated Coengagement of FcγRIIb and B Cell Receptor Complex Suppresses Humoral Immunity in Systemic Lupus Erythematosus

J. Desjarlais, D. Szymkowski, J. Zalevsky, 2011, The Journal of Immunology.

Transgene-mediated cosuppression in the C. elegans germ line.

A. Villeneuve, A. Dernburg, J. Zalevsky, 2000, Genes & development.

Crossing over during Caenorhabditis elegans meiosis requires a conserved MutS-based pathway that is partially dispensable in budding yeast.

K. Kemphues, A. Villeneuve, J. Zalevsky, 1999, Genetics.

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion

A. Nicosia, Rosa Bartolomeo, J. Zalevsky, 2021, Journal for ImmunoTherapy of Cancer.

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).

S. Gettinger, M. Hurwitz, P. Hwu, 2020, Cancer discovery.

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.

M. Hurwitz, P. Hwu, C. Hudgens, 2019, Cancer discovery.

Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies.

M. Perales, C. Turtle, J. Zalevsky, 2021, Future oncology.

Different WASP family proteins stimulate different Arp2/3 complex-dependent actin-nucleating activities

R. Mullins, J. Zalevsky, Jonathan Zalevsky, 2001, Current Biology.

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

K. Rajapakshe, C. Coarfa, M. Hurwitz, 2020, Nature Communications.

Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants

Eugene A Zhukovsky, John R Desjarlais, Cheryl Chan, 2003, Science.

PanR1, a Dominant Negative Missense Allele of the Gene Encoding TNF-α (Tnf), Does Not Impair Lymphoid Development1

B. Dahiyat, B. Beutler, J. Zalevsky, 2006, The Journal of Immunology.

Bempegaldesleukin (BEMPEG; NKTR‐214) efficacy as a single agent and in combination with checkpoint‐inhibitor therapy in mouse models of osteosarcoma

E. Kleinerman, J. Zalevsky, S. Kivimäe, 2020, International journal of cancer.

Efficacy and immune modulation by BXCL701 a dipeptidyl peptidase inhibitor, NKTR-214 a CD122-biased immune agonist with PD1 blockade in murine pancreatic tumors.

Zeenia Jagga, J. Zalevsky, D. Charych, 2018 .

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy

W. Rubas, J. Zalevsky, Vidula Dixit, 2017, PloS one.

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2R af Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

M. Hurwitz, P. Hwu, C. Hudgens, 2019 .

NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential

W. Rubas, D. Gauvin, J. Zalevsky, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Engineering fully human monoclonal antibodies from murine variable regions.

John R Desjarlais, Greg A Lazar, J. Desjarlais, 2010, Journal of molecular biology.

NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases

J. Ritz, W. Rubas, C. Fanton, 2021, Journal of translational autoimmunity.

The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates.

J. Desjarlais, E. Zhukovsky, J. Zalevsky, 2009, Blood.

Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab

S. Riddell, J. Zalevsky, S. Tykodi, 2020, Journal for ImmunoTherapy of Cancer.

Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study.

J. Henningfield, J. Zalevsky, M. Tagliaferri, 2019, Pain medicine.

In vivo and in vitro Characterization of a Partial Mu Opioid Receptor Agonist, NKTR-181, Supports Future Therapeutic Development

C. Cahill, J. Zalevsky, W. Walwyn, 2021, Frontiers in Pain Research.

Engineering IL-2 to Give New Life to T Cell Immunotherapy.

J. Zalevsky, M. Tagliaferri, W. Overwijk, 2020, Annual review of medicine.

Activation of the Arp2/3 Complex by the Listeria ActA Protein

I. Grigorova, R. Mullins, J. Zalevsky, 2001, The Journal of Biological Chemistry.

Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial).

J. Brugarolas, F. Cattaruzza, J. Zalevsky, 2019, Journal of Clinical Oncology.

A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors.

M. Hurwitz, P. Hwu, M. Sznol, 2017 .

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

M. Hurwitz, M. Sznol, A. Balar, 2022, Journal for ImmunoTherapy of Cancer.

Activation of the Arp 2 / 3 Complex by the Listeria ActA Protein ActA BINDS TWO ACTIN MONOMERS AND THREE SUBUNITS OF THE Arp 2 / 3 COMPLEX *

I. Grigorova, R. Mullins, J. Zalevsky, 2001 .

Abstract B057: The CD122-biased immunostimulatory cytokine NKTR-214 combined with checkpoint blockade leads to mobilization of antitumor immunity and synergistic activity

J. Zalevsky, M. Addepalli, S. Doberstein, 2016 .

Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.

M. Hurwitz, P. Hwu, M. Tetzlaff, 2017 .

Abstract 3755: Comprehensive antitumor immune activation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214

W. Rubas, C. Fanton, J. Zalevsky, 2018, Immunology.

Abstract 1603: NKTR-255 engages the IL-15 pathway driving CD8 T cell survival and CD8 memory T cell proliferation

C. Fanton, J. Zalevsky, M. Addepalli, 2017 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential

W. Rubas, D. Gauvin, J. Zalevsky, 2017, The Journal of Pharmacology and Experimental Therapeutics.

NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.

M. Fishman, Jianjun Gao, A. Balar, 2019, Journal of Clinical Oncology.